-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 30, Sichuan State submitted a generic listing application for dapagliflozin tablets for pharmaceuticals
Figure 1: The status of companies reporting for the production of dapagliflozin tablets recently
Source: CDE official website
Dapagliflozin is a new oral hypoglycemic drug developed by Bristol-Myers Squibb (which has been transferred to AstraZeneca).
According to data from Meinnet.
Figure 2: The market size of oral hypoglycemic drugs in the retail market
Source: Mi Nei.
Table 1: TOP5 oral hypoglycemic drugs in the retail market
Source: Mi Nei.
In Chinese urban physical pharmacies, the market size of oral hypoglycemic drugs is expected to remain above 5 billion yuan in 2021.
AstraZeneca’s monopoly of the dapagliflozin market has ended.
Source: CDE official website, Minet database
Statistics are as of December 1.